Figure 1.

Selection of empirical and targeted therapy episodes

DTR=difficult-to-treat resistance. GNI=Gram-negative infections. DOT=days of therapy. *See appendix p 4 for list of organisms of interest. †Sites of interest: blood, gastrointestinal, urine, intra-abdominal, skin and soft tissue, respiratory, secondary bacteraemia, and other. ‡Polymicrobial counts represent each isolate identified in a culture individually. §Conservative estimate based on 1–2 days of colistin or polymyxin B. ¶Liberal estimates based on 1–2 of colistin or polymyxin B and aminoglycosides (amikacin, tobramycin, and gentamicin). ||Lower bound determined with site-specific DOT multiplier and upper bound limited based on 14-day multiplier for all sites. **Overall market is the summation of conservative empirical market and targeted DTR (site-specific multiplier) and upper bound limited based on summation of liberal empirical market and targeted DTR (14-day multiplier for all sites).